Key findings from SURMOUNT-1 include a mean weight loss of 15.0% at the 5mg dose, 19.5% at the 10mg dose, and 20.9% at the 15mg dose over 72 weeks
NAD+ or SS-31 improved mitochondrial repair and oxidative resilience
Casgevy, developed by Vertex Pharmaceuticals and CRISPR Therapeutics, has been hailed as curative for sickle cell disease (SCD) patients
Durham Peptides Mar 22 3 min read BPC-157 and TB-500 are the two most discussed recovery-related research peptides in Canada
Preclinical safety at tested doses has been reasonable, but human long-term safety data are not established
What it may miss It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation